Skip to search formSkip to main contentSkip to account menu

Bextra

Known as: Pfizer brand of valdecoxib 
a kind of nonsteroidal anti-inflammatory drugs
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

valdecoxib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Legal and Economic Perspectives Concerning US Government Investigations of Alleged Off-Label Promotion by Drug Manufacturers
Over the past few years, many pharmaceuticalmanufacturers have settled claims brought bythe US Department of Justice (USDOJ… 
Review
2008
Review
2008
Crunch time for peer review in lawsuit
A US magistrate is set to rule next week on whether the drugmaker Pfizer can force The New England Journal of Medicine (NEJM) to… 
2006
2006
Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?
In this issue of the Journal of Clinical Oncology, Smith et al report that celecoxib use may reduce the mean prostate-specific… 
2006
2006
Pharma's year of trouble and strife
Safety in the spotlight The year began, much as 2004 had ended, with Vioxx (rofecoxib; Merck) and the other cyclooxygenase-2… 
2005
2005
Speech transcript stokes opposition to Harvard head
University president Larry Summers under fire for remarks on women in science. 
Review
2005
Review
2005
Pfizer withdraw valdecoxib (Bextra) at Health Canada's request
  • B. Sibbald
  • Canadian Medical Association Journal
  • 2005
  • Corpus ID: 71130581
that Pfizer Canada has voluntarily withdrawn valdecoxib (Bextra) from the market pending the resolution of safety issues. Health… 
2005
2005
Vioxx Verdict: Too Little or Too Much Science?
THE LAWA widow's victory in the first of thousands of cases against Merck's pain reliever sidesteps important questions about the… 
2005
2005
Bextra Withdrawn From Market
2005
2005
Coxib medications to be handled with care
Reasons for posting: On December 17, 2004, Pfizer and the US National Cancer Institute announced that they have stopped… 
2004
2004
FDA will increase postmarketing surveillance of drugs
Drug regulators will be barred from having any links to the pharmaceutical industry under new measures announced last week. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)